Abstract
ADJUVANTS are widely used to increase antibody formation in experimental animals, for example, Freund's incomplete adjuvant, a water-in-oil emulsion containing the antigen, and Freund's complete adjuvant, which is the same but with killed tubercle bacilli. These adjuvants cannot be used in man because the mineral oil base is not degraded and persists at the injection site. Particularly with the complete adjuvant, unacceptable granulomas can be formed. There is real need for a safe and effective adjuvant for use in human immunisation programmes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gregoriadis, G., and Buckland, R. A., Nature, 244, 170–172 (1973).
Gregoriadis, G., Swain, C. P., Wills, E. J., and Tavill, A. S., Lancet, i, 1313–1316 (1974).
Gregoriadis, G., and Allison, A. C., FEBS Lett., 44, 71–74 (1973).
Faulk, P. W., and Houba, V., J. Immun. Meth., 3, 87–98 (1973).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
ALLISON, A., GREGORIADIS, G. Liposomes as immunological adjuvants. Nature 252, 252 (1974). https://doi.org/10.1038/252252a0
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1038/252252a0
This article is cited by
-
Liposomes for malaria management: the evolution from 1980 to 2020
Malaria Journal (2021)
